{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"62"},{"groupId":"OG003","value":"48"}]}],"title":"Imatinib-resistant Mutations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}],"title":"Mutations with unknown Imatinib-resistance status"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"63"},{"groupId":"OG003","value":"50"}]}],"title":"Imatinib Resistant or unknown mutations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Polymorphisms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"86"},{"groupId":"OG003","value":"96"}]}],"title":"No Mutations"}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"146"}],"units":"Participants"}],"description":"BCR-ABL mutations were assessed in participants prior to the start of study drug (baseline) and at the time of disease progression or at end of therapy. Quantification of BCR-ABL transcripts in peripheral blood was evaluated using quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR, RT-PCR).","groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.\n\nAfter the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All randomized, treated participants with available mutation data were summarized.","reportingStatus":"POSTED","timeFrame":"Baseline up to 24 months","title":"Number of Participants With MCyR and Baseline BCR-ABL Gene Mutation - All Treated Participants","type":"SECONDARY","unitOfMeasure":"participants"}